Results from the Phase II C-144-01 trial showed that a single infusion of Amtagvi demonstrated a 31.4% objective response ...

Many Americans struggle with being overweight, social stigmas still prevent people from talking to doctors and seeking ...

Skin cancer is often overlooked by many Americans, who are at elevated risk for being over exposed to the sun in the summer ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Fidelis Care announced that it is using Men’s Health Month as an opportunity to promote important health tips that men should ...

The drinks contain a mix of protein and vitamins that will help GLP-1 users reduce weight in a healthy manner.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...

New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...

The industry is facing challenges from the new administration that could have serious impacts on everything from market ...

New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong ...

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...